echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > One patient died in a Phase II/III study of gene therapy type IIIA adhesive polysaccharose storing disorder.

    One patient died in a Phase II/III study of gene therapy type IIIA adhesive polysaccharose storing disorder.

    • Last Update: 2020-10-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Lysogene disclosed Thursday that one patient in the Phase II/III AAVance study died and is undergoing gene therapy LYS-SAF302 to treat type IIIA adhesive polysaccharose storage disorder (MPS IIIA).
    Lysogene's share price fell as much as 19 percent on the news, and the cause of death is not yet known, but there is no evidence linking the death to LYS-SAF302.
    LYS-SAF302, a gene therapy for MPS IIIA developed by Lysogene, is a gene therapy mediated by adenopathic viruses (AAVs) that aims to replace defective SGSH genes by delivering functional SGSH genes through AAV.
    three elements of research gene therapy (LYS-SAF302) for MPS IIIA are: vector: AAVrh10 initiater: CAG delivery gene: complete SGSH gene Lysogene said it would study the remaining 18 patients "strictly in accordance with the research program."
    picture source:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.